Cancer Patient Can Use Newton Firm’s Drug, FDA Says

Pro-Pharmaceuticals of Newton, MA, announced today that it got the go-ahead from the FDA to treat one breast cancer patient with its lead drug candidate, Davanat. The drug, a carbohydrate polymer currently in Phase II trials for colorectal and biliary cancers, is designed to be used in combination with other cancer treatments.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy